We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+17.28%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.14B
AUM Growth
-$43.5M
Cap. Flow
+$1.54M
Cap. Flow %
0.14%
Top 10 Hldgs %
61.62%
Holding
73
New
4
Increased
21
Reduced
29
Closed
16

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$37.9M
2
INSP icon
Inspire Medical Systems
INSP
+$25.6M
3
IMGN
Immunogen Inc
IMGN
+$14.9M
4
RVTY icon
Revvity
RVTY
+$14.5M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$12.1M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$23.8M
2
DHR icon
Danaher
DHR
+$16.2M
3
NTRA icon
Natera
NTRA
+$12M
4
AMRX icon
Amneal Pharmaceuticals
AMRX
+$11.2M
5
GSK icon
GSK
GSK
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.59%
2 Miscellaneous 10.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CVAC
51
DELISTED
CureVac
CVAC
$2.09M 0.18%
496,912
-19,882
-4% -$108K
RGEN icon
52
Repligen
RGEN
$9.95B
$1.8M 0.16%
9,984
-6,169
-38% -$960K
XOMA
53
DELISTED
Xoma
XOMA
$1.73M 0.15%
93,727
+3,777
+4% +$62.2K
JBIO
54
Jade Biosciences
JBIO
$1.33B
$1.14M 0.1%
1,435
– –
AFMD
55
DELISTED
Affimed
AFMD
$1.05M 0.09%
167,668
– –
HUM icon
56
Humana
HUM
$46.3B
$876K 0.08%
1,914
-16,207
-89% -$7.99M
ACIU icon
57
AC Immune
ACIU
$263M
$623K 0.05%
124,589
– –
AMN icon
58
PUT
AMN Healthcare
AMN
$1.34B
– –
-50,000
Closed -$4.26M
AMRX icon
59
Amneal Pharmaceuticals
AMRX
$6.11B
– –
-2,644,988
Closed -$11.2M
APLS
60
DELISTED
Apellis Pharmaceuticals
APLS
– –
-122,643
Closed -$4.67M
BBIO icon
61
PUT
BridgeBio Pharma
BBIO
$15B
– –
-55,800
Closed -$1.47M
BDTX icon
62
Black Diamond Therapeutics
BDTX
$128M
– –
-337,131
Closed -$968K
HYG icon
63
PUT
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$17.6B
– –
-90,000
Closed -$6.63M
IBB icon
64
PUT
iShares Biotechnology ETF
IBB
$10.5B
– –
-70,300
Closed -$8.6M
MEDP icon
65
Medpace
MEDP
$16.8B
– –
-8,823
Closed -$2.14M
MRVI icon
66
Maravai LifeSciences
MRVI
$1.14B
– –
-452,323
Closed -$4.52M
PNTG icon
67
Pennant Group
PNTG
$1.3B
– –
-365,899
Closed -$4.07M
PODD icon
68
Insulet
PODD
$10.1B
– –
-21,299
Closed -$3.4M
TLT icon
69
PUT
iShares 20+ Year Treasury Bond ETF
TLT
$46.8B
– –
-93,700
Closed -$8.31M
XBI icon
70
State Street SPDR S&P Biotech ETF
XBI
$11.3B
– –
-20,000
Closed -$1.46M
XBI icon
71
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.3B
– –
-80,000
Closed -$5.84M
WHWK
72
Whitehawk Therapeutics
WHWK
$263M
– –
-101,918
Closed -$493K
HZNP
73
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-205,815
Closed -$23.8M
1 2
3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q4 2023 Portfolio in Review

As of Q4 2023, Eversept Partners held 73 positions worth $1.14B, down 3.7% from $1.18B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Eversept Partners's Q4 2023 filing shows 4 new, 21 increased, 29 reduced and 16 closed positions. Its largest new stake was Immunogen Inc: 748,950 shares worth $22.2M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $23.8M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 76% a quarter earlier, followed by Miscellaneous.

  • Eversept Partners's largest Q4 2023 buy was Immunogen Inc: 748,950 shares worth $22.2M.
  • Eversept Partners added most to argenx in Q4 2023, an estimated $37.9M increase.
  • Eversept Partners's biggest Q4 2023 reduction was Danaher, cutting an estimated $16.2M.
  • Eversept Partners fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $23.8M.
  • Eversept Partners's ten largest holdings make up 62% of its $1.14B portfolio in Q4 2023.
  • Eversept Partners opened 4 new positions and closed 16 in Q4 2023.
  • Eversept Partners's portfolio value fell 3.7% quarter-over-quarter to $1.14B.

Based on Eversept Partners's 13F filing for Q4 2023, filed 14 Feb 2024.